Biofrontera (NASDAQ:BFRIW – Get Free Report) is anticipated to issue its results before the market opens on Thursday, March 19th. Analysts expect the company to announce earnings of $0.1950 per share and revenue of $16.1460 million for the quarter.
Biofrontera Price Performance
BFRIW remained flat at $0.06 during trading hours on Thursday. The company had a trading volume of 3,200 shares, compared to its average volume of 1,335. The stock has a 50 day simple moving average of $0.06 and a 200-day simple moving average of $0.08. Biofrontera has a 52-week low of $0.03 and a 52-week high of $0.28.
About Biofrontera
Biofrontera AG is a biopharmaceutical company headquartered in Leverkusen, Germany, specializing in the development, manufacture and commercialization of dermatology products. Founded in 1997, the company focuses on therapies for skin diseases through innovative drug and device combinations. Its core business centers on photodynamic therapy, where a photosensitizing agent is activated by a specialized light source to treat precancerous and cancerous skin conditions.
The company’s flagship product, Ameluz, is a topical formulation of aminolevulinic acid used in conjunction with the BF-RhodoLED irradiation device.
Recommended Stories
- Five stocks we like better than Biofrontera
- Gold’s Big Move May Be Creating Early Opportunities
- The largest IPO in history is coming
- Read this or regret it forever
- Trump’s NEW Executive Order – BIG Changes Coming to Retirement Accounts
- Only 500 people today…
Receive News & Ratings for Biofrontera Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Biofrontera and related companies with MarketBeat.com's FREE daily email newsletter.
